Cogstate Limited

Equities

CGS

AU000000CGS8

Biotechnology & Medical Research

Market Closed - Australian S.E. 02:10:45 2024-04-26 am EDT 5-day change 1st Jan Change
1.37 AUD +3.40% Intraday chart for Cogstate Limited +5.38% -5.19%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment MT
Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% MT
Cogstate Limited authorizes a Buyback Plan. CI
Transcript : Cogstate Limited, H1 2024 Earnings Call, Feb 22, 2024
Cogstate Limited announces an Equity Buyback for 5,000,000 shares, representing 2.92% of its issued share capital. CI
Cogstate Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Cogstate Ends Share Buyback Program MT
Cogstate Limited's Equity Buyback announced on February 28, 2023 has closed with 3,753,218 shares, representing 2.17% for AUD 5.59 million. CI
Tranche Update on Cogstate Limited's Equity Buyback Plan announced on February 28, 2023. CI
Transcript : Cogstate Limited - Special Call
Cogstate Joins Forces to Establish Dementia Insurance in Japan MT
Cogstate Limited Announces Change of Registered Office and Principal Place of Business CI
Cogstate Limited Provides Revenue Guidance for 2024 CI
Transcript : Cogstate Limited, 2023 Earnings Call, Aug 22, 2023
Tranche Update on Cogstate Limited's Equity Buyback Plan announced on February 28, 2023. CI
Cogstate Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023 CI
Cogstate Limited Appoints Kristi Geddes as Company Secretary CI
Cogstate Limited Provides Revenue Guidance in the Fourth Quarter 2023 CI
Cogstate Limited Reports Revenue Results for the Quarter and Year to Date Ended 31 March 2023 CI
Transcript : Cogstate Limited, H1 2023 Earnings Call, Feb 28, 2023
Cogstate Limited authorizes a Buyback Plan. CI
Cogstate Limited announces an Equity Buyback for AUD 13 million worth of its shares. CI
Cogstate Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Cogstate Limited Revises Earnings Guidance for the Fiscal Year Ending 30 June 2023 CI
Chart Cogstate Limited
More charts
Cogstate Ltd is a neuroscience technology company. It is engaged in the creation, validation, and commercialization of digital brain health assessments and design and assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments. Its segments include Clinical Trials, Healthcare, and Research. The Clinical Trials segment includes adoption of decentralized clinical trial methodologies and scientific publication and marketing of the utility and validity of Cogstate technology. The Healthcare segment includes Cognigram, which allows for regular and standardized testing to assist in the early detection of cognitive decline that could be related to a range of factors including head injury, neurodegenerative disease or side effects following pharmacological treatments. The Research segment includes research studies and academic collaborations across various indications, such as Alzheimer’s disease and Parkinson’s disease.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.37 AUD
Average target price
1.8 AUD
Spread / Average Target
+31.39%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. CGS Stock
  4. News Cogstate Limited
  5. Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%